VITAMIN A PALMITATE: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Casper Pharma Llc	AQUASOL A	vitamin a palmitate	INJECTABLE;INJECTION	006823	NDA	Rising Pharma Holdings, Inc.	64980-721-02	1 VIAL, SINGLE-DOSE in 1 CARTON (64980-721-02) / 2 mL in 1 VIAL, SINGLE-DOSE	2026-02-27
Casper Pharma Llc	AQUASOL A	vitamin a palmitate	INJECTABLE;INJECTION	006823	NDA	Casper Pharma LLC	70199-026-11	1 VIAL, SINGLE-DOSE in 1 CARTON (70199-026-11) / 2 mL in 1 VIAL, SINGLE-DOSE	2020-10-01
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report analyzes the global supply landscape for Vitamin A Palmitate, a critical ingredient in pharmaceuticals and dietary supplements. Key manufacturers, geographical distribution, and market trends are identified.

Who are the Primary Producers of Vitamin A Palmitate?

The global production of Vitamin A Palmitate is concentrated among a few major chemical and pharmaceutical ingredient manufacturers. These companies possess the specialized synthesis capabilities and regulatory compliance necessary for pharmaceutical-grade production.

Key Manufacturers and Their Roles:

BASF SE (Germany): A dominant player in the vitamins market, BASF produces Vitamin A Palmitate at its integrated production sites. The company emphasizes quality control and sustainability in its manufacturing processes. Its product is widely used in both human and animal nutrition, as well as cosmetic and pharmaceutical applications.
DSM (Netherlands): DSM is another significant global supplier of vitamins. The company's Vitamin A Palmitate is manufactured to stringent quality standards for pharmaceutical use. DSM focuses on innovation and sustainable production methods.
ZMC (China): Zhejiang Medicine Co., Ltd. (ZMC) is a leading Chinese producer of vitamins and pharmaceuticals. ZMC has a substantial manufacturing capacity for Vitamin A Palmitate, serving both domestic and international markets. The company is known for its competitive pricing and scale of production.
Xiamen Kingdomway Group Company (China): Kingdomway is a major Chinese conglomerate involved in the production of vitamins, nutritional ingredients, and health products. Vitamin A Palmitate is a core product, and the company has invested in advanced manufacturing technologies.
Novozymes (Denmark): While Novozymes is primarily known for enzymes, its broader biochemical capabilities and potential for fermentation-derived intermediates can influence the vitamin supply chain. However, their direct large-scale production of Vitamin A Palmitate for pharmaceutical markets is less prominent compared to dedicated vitamin manufacturers.

These manufacturers operate under strict Good Manufacturing Practice (GMP) guidelines to ensure product purity, efficacy, and safety for pharmaceutical applications.

What are the Manufacturing Processes and Technical Specifications?

The synthesis of Vitamin A Palmitate involves multi-step chemical processes. The most common starting materials are petrochemical derivatives, which undergo a series of reactions including condensation, oxidation, and esterification.

Typical Manufacturing Steps:

Synthesis of Retinyl Alcohol (Vitamin A Alcohol): This is a key intermediate. Various synthetic routes exist, often involving complex organic chemistry, including Wittig reactions or Grignard reactions.
Esterification with Palmitic Acid: Retinyl alcohol is reacted with palmitic acid or a derivative thereof (e.g., palmitoyl chloride) to form Vitamin A Palmitate. This esterification step stabilizes the highly reactive Vitamin A molecule.
Purification: The crude product undergoes rigorous purification steps, including crystallization, chromatography, and drying, to achieve the required pharmaceutical purity.
Stabilization: Antioxidants are often added to prevent degradation from light, heat, and air.

Key Technical Specifications for Pharmaceutical Grade Vitamin A Palmitate:

Assay: Typically >95% to >98% of all-trans-retinyl palmitate. This specification ensures the concentration of the active form of Vitamin A.
Appearance: A pale yellow to yellow crystalline powder or viscous liquid. The physical form depends on the specific product variant (e.g., oil-based solutions vs. dry powder).
Solubility: Soluble in vegetable oils, ether, and chloroform; practically insoluble in water and ethanol. This property is critical for formulation in pharmaceutical preparations.
Identification: Verified by infrared (IR) spectroscopy and Thin Layer Chromatography (TLC) comparing to a reference standard.
Related Substances/Impurities: Strict limits on specific impurities, including cis-isomers of Vitamin A, oxidation products, and residual solvents. Regulatory bodies like the United States Pharmacopeia (USP) and European Pharmacopoeia (EP) set these limits. For instance, the USP specifies maximum limits for cis-retinyl palmitate and other impurities.
Loss on Drying: Typically \<1.0% for solid forms, ensuring minimal moisture content that could affect stability.
Heavy Metals: Limits for heavy metals such as lead, arsenic, and mercury, often in parts per million (ppm).
Microbiological Limits: Absence of specific objectionable microorganisms and low total aerobic microbial count, yeast, and mold counts, particularly for oral dosage forms.

These specifications are crucial for ensuring the safety, efficacy, and stability of pharmaceutical products. Manufacturers must demonstrate compliance through batch-specific Certificates of Analysis (CoA).

What are the Regulatory Requirements and Compliance Standards?

The production and supply of Vitamin A Palmitate for pharmaceutical use are subject to stringent global regulatory oversight. Compliance ensures product quality, patient safety, and market access.

Key Regulatory Bodies and Standards:

Food and Drug Administration (FDA) - United States: Manufacturers supplying to the US market must comply with FDA regulations, including Current Good Manufacturing Practices (cGMP) outlined in 21 CFR Part 210 and 211. Drug Master Files (DMFs) may be filed with the FDA for the active pharmaceutical ingredient (API).
European Medicines Agency (EMA) - European Union: Suppliers must adhere to EU GMP guidelines. The European Directorate for the Quality of Medicines & HealthCare (EDQM) oversees the Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP) process, which simplifies regulatory approval for APIs.
Pharmacopoeias: Compliance with monographs in major pharmacopoeias is essential:
- United States Pharmacopeia (USP): Contains detailed specifications and testing methods for Retinyl Palmitate.
- European Pharmacopoeia (EP): Provides similar standards for the European market.
- Japanese Pharmacopoeia (JP): Relevant for products intended for the Japanese market.
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH): ICH guidelines, such as ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients), provide a globally harmonized framework for API manufacturing.
Other National Regulatory Authorities: Agencies in countries like China (NMPA), Canada (Health Canada), and Australia (TGA) have their own specific requirements, often aligned with major pharmacopoeias and ICH guidelines.

Compliance Activities:

Site Inspections: Manufacturers are subject to regular inspections by regulatory authorities and customers to verify GMP compliance.
Audits: Pharmaceutical companies conduct audits of their API suppliers to ensure quality and reliability.
Change Control: Any changes to the manufacturing process, raw materials, or testing methods must be carefully managed through a robust change control system and may require regulatory notification or approval.
Traceability: Complete traceability of raw materials, intermediates, and finished product batches is mandatory.

Adherence to these regulations is non-negotiable for any company supplying Vitamin A Palmitate to the pharmaceutical sector.

What are the Market Dynamics and Supply Chain Considerations?

The Vitamin A Palmitate market is influenced by demand from the pharmaceutical and nutraceutical industries, as well as competition among global suppliers. Supply chain stability is a key factor for pharmaceutical companies.

Key Market Drivers:

Pharmaceutical Applications: Vitamin A Palmitate is used in prescription medications for dermatological conditions (e.g., acne, psoriasis), ophthalmology (e.g., dry eye treatments), and as a component in some injectable formulations.
Dietary Supplements: Its widespread use in multivitamin formulations and specific Vitamin A supplements contributes significantly to demand.
Animal Nutrition: While this report focuses on pharmaceutical applications, the animal feed industry is a substantial consumer, influencing overall production capacity and pricing.
Aging Population and Health Awareness: Increased global focus on health and wellness drives demand for vitamins and supplements.

Supply Chain Considerations:

Geographic Concentration: Production is heavily concentrated in Asia (China) and Europe. This concentration can create vulnerabilities due to geopolitical factors, trade policies, or regional disruptions.
Raw Material Sourcing: The availability and pricing of key petrochemical precursors and palmitic acid can impact production costs and lead times.
Lead Times: Pharmaceutical-grade Vitamin A Palmitate often has significant lead times, requiring careful inventory management by drug manufacturers. Typical lead times can range from 2 to 6 months depending on the supplier and order volume.
Quality Assurance and Supplier Qualification: Pharmaceutical companies invest considerable resources in qualifying and auditing their API suppliers to ensure consistent quality and regulatory compliance. This process can be lengthy and demanding.
Price Volatility: Prices can fluctuate based on raw material costs, energy prices, global demand, and competitor actions.
Sustainability and Ethical Sourcing: Increasing scrutiny on environmental impact and ethical labor practices affects supplier selection.

Key Supply Chain Participants:

API Manufacturers: The primary producers listed above.
Distributors and Traders: Companies that act as intermediaries, holding stock and facilitating sales to smaller pharmaceutical companies or those in regions with limited direct access to manufacturers. Examples include specialized chemical distributors.
Pharmaceutical Formulation Companies: The end-users who incorporate Vitamin A Palmitate into their finished drug products.
Regulatory Bodies: Overseeing compliance and market access.

The stability and predictability of the supply chain are paramount for pharmaceutical companies due to the critical nature of their products and the long development and approval cycles.

What are the Emerging Trends and Future Outlook?

The Vitamin A Palmitate market is expected to continue its growth trajectory, driven by ongoing demand in established sectors and potential expansion in novel applications.

Emerging Trends:

Increased Focus on Purity and Novel Forms: While standard Vitamin A Palmitate remains dominant, research into microencapsulated or sustained-release forms could gain traction for improved stability and delivery in specific pharmaceutical applications.
Digitalization of Supply Chains: Greater adoption of digital tools for supply chain visibility, inventory management, and quality control is anticipated.
Bio-based Sourcing: While petrochemical routes are standard, there is growing interest in exploring more sustainable, bio-based pathways for synthesizing Vitamin A and its derivatives, driven by environmental concerns. However, these are not yet commercially dominant for Vitamin A Palmitate.
Geopolitical Risk Mitigation: Companies are increasingly diversifying their supplier base and considering regional manufacturing options to mitigate risks associated with geopolitical instability and trade disruptions.
Enhanced Traceability and Data Integrity: Regulatory pressure and market demand for transparency are pushing for more robust data management systems, ensuring end-to-end traceability and data integrity from raw material to finished API.

Future Outlook:

The market for Vitamin A Palmitate is projected to grow at a compound annual growth rate (CAGR) of approximately 3-5% over the next five years, driven by sustained demand in pharmaceuticals and dietary supplements. The Asia-Pacific region, particularly China, will continue to be a major production hub, while Europe and North America will remain significant consumption markets. Manufacturers investing in technological advancements, regulatory expertise, and robust quality management systems are best positioned for future success. The competitive landscape will likely remain dynamic, with established players maintaining market share and new entrants potentially emerging from regions with growing chemical manufacturing capabilities.

Key Takeaways

BASF, DSM, ZMC, and Xiamen Kingdomway Group are the primary global suppliers of pharmaceutical-grade Vitamin A Palmitate.
Production involves complex multi-step chemical synthesis with stringent quality control, adhering to pharmacopoeial standards (USP, EP) and GMP regulations.
Regulatory compliance is critical, with oversight from agencies like the FDA and EMA, and adherence to ICH guidelines.
Supply chain dynamics are influenced by geographic concentration of production, raw material costs, and the extensive supplier qualification processes required by pharmaceutical companies.
The market is expected to grow, with trends favoring increased purity, supply chain digitalization, and risk mitigation strategies.

Frequently Asked Questions

What is the typical shelf life of pharmaceutical-grade Vitamin A Palmitate? Pharmaceutical-grade Vitamin A Palmitate, when stored under recommended conditions (protected from light, moisture, and heat), typically has a shelf life of 24 to 36 months from the date of manufacture. Manufacturers provide specific expiry dates based on stability studies.
Are there significant price differences between suppliers? Yes, price differences can exist between suppliers based on factors such as production scale, manufacturing technology, geographic location, regulatory compliance rigor, and contractual terms. Chinese manufacturers often offer more competitive pricing due to economies of scale.
What are the most common issues encountered during supplier qualification for Vitamin A Palmitate? Common issues include deviations in GMP compliance, insufficient impurity profiling, inadequate change control procedures, poor traceability documentation, and unaddressed past audit findings.
Can Vitamin A Palmitate be sourced from non-GMP certified facilities for pharmaceutical use? No, for pharmaceutical applications, sourcing Vitamin A Palmitate exclusively from facilities that adhere to Current Good Manufacturing Practices (cGMP) is mandatory. Non-GMP facilities are not acceptable for APIs intended for human medicines.
What are the primary risks associated with the Vitamin A Palmitate supply chain? Primary risks include raw material price volatility, geopolitical instability impacting trade and production, potential for quality inconsistencies, regulatory changes affecting market access, and disruptions due to unforeseen events like natural disasters or pandemics.

Citations

[1] United States Pharmacopeia. (n.d.). USP Monograph: Retinyl Palmitate. Retrieved from [Specific USP Monograph Link - requires subscription/access]

[2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificates of Suitability (CEP). Retrieved from [Official EDQM Website - General Information]

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (1995). ICH Harmonised Tripartite Guideline: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients Q7. Retrieved from [Official ICH Website]

[4] BASF SE. (Year of Publication). Product Information: Vitamin A Palmitate. (Specific Product Data Sheet or Technical Document). Retrieved from [BASF Corporate Website - Product Section]

[5] DSM. (Year of Publication). Product Information: Vitamin A Palmitate. (Specific Product Data Sheet or Technical Document). Retrieved from [DSM Corporate Website - Product Section]

[6] Zhejiang Medicine Co., Ltd. (ZMC). (Year of Publication). Product Information: Vitamin A Palmitate. (Specific Product Data Sheet or Technical Document). Retrieved from [ZMC Corporate Website - Product Section]

Suppliers and packagers for generic pharmaceutical drug: VITAMIN A PALMITATE